AbD Serotec

This story has been updated from a previous version to include comments from Bio-Rad's earnings call.

NEW YORK (GenomeWeb News) - Bio-Rad Laboratories said today that it has closed its acquisition of antibody manufacturer AbD Serotec, a division of MorphoSys, for around €53 million ($70 million) in cash.

NEW YORK (GenomeWeb News) – Bio-Rad Laboratories announced yesterday that it has signed a definitive agreement to acquire antibody manufacturer AbD Serotec for €53 million ($69.7 million) in cash.

Morphosys said it has agreed to a three-year extension of its ongoing research partnership with Japanese pharma firm Shionogi.

Morphosys announced that its AbD Serotec division has signed an agreement with the Moredun Research Institute and the University of Edinburgh's Roslin Institute to develop reagents for veterinary research.

The agreement grants Merck access to the company's HuCAL Gold antibody library for research purposes, as well as the option to upgrade to Morphosys's HuCAL Platinum library.

The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.

The New York Times reports that United Nations delegates have been discussing how to govern the genetic resources of the deep sea.

Researchers have transplanted edited cells into mice that appear to combat cocaine addiction, New Scientist reports.

In PNAS this week: analysis of proteolytic enzymes secreted by circulating tumor cells, phylogenetic study of Fv1 evolution, and more.